CALT - Calliditas Therapeutics Revenue Growth YoY (Last 12 Months)

Calliditas Therapeutics (CALT) minimizes risks by focusing on therapies for rare nephrological pathologies with high demand. The GURU.Markets platform reflects the year-over-year sales trajectory (TTM), where the 178.60 indicator determines the metric's magnitude. Calliditas Therapeutics is striving for the expansion of the drug Tarpeyo to capture market share, while support from a European behemoth and a 100% patient retention rate strengthen its regulatory status.
calliditas.se (CALT) - metric breakdowns and financial figures

This indicator measures the rolling revenue growth rate over the last 12 months, allowing for the capture of real-time market shifts prior to the publication of official reports. By analyzing year-over-year sales growth (TTM), an investor assesses the effectiveness of Calliditas Therapeutics (CALT) expansion into new markets and the successful implementation of rare kidney disease therapies supported by insurance companies.